Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single-arm, Open-label Use of Hemlibra (Emicizumab) to Treat Hemophilic Pseudotumor

NCT03921294 is registered in ClinicalTrials.gov with Indiana Hemophilia &Thrombosis Center, Inc. as lead sponsor.

NCT NCT03921294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03921294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single-arm, Open-label Use of Hemlibra (Emicizumab) to Treat Hemophilic Pseudotumor
Lead sponsor
Indiana Hemophilia &Thrombosis Center, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
May 15, 2019
Completion date
March 16, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilic pseudotumour